Abstract. The constitutive activation of JNK has been implicated in Ras-induced cellular transformation and activated JNK is down-regulated by the tumor suppressor protein, RASSF1A. In this study, we examined whether RASSF1A blocked oncogenic Ras-induced JNK activation. Exogenous expression of H-Ras G12V induced JNK phosphorylation and RASSF1A co-transfected with H-Ras G12V efficiently suppressed Ras-triggered JNK activation in various cancer cell lines. RASSF1A expression revived the H-Ras G12V -induced p27
Introduction
Many tumor suppressors are usually inactivated by loss of heterozygosity (LOH) mutation, or epigenetic inactivation during tumorigenesis. RASSF1A is also inactivated by LOH or by hypermethylation of its promoter region, resulting in its loss of expression in a variety of human cancers (1) (2) (3) . The exact role of RASSF1A as a tumor suppressor is not fully understood, despite considerable study. Many tumor suppressors, such as Rb and p53, control the cell cycle, and their inactivation results in the failure of cell-cycle regulation, consequently contributing to tumorigenesis. RASSF1A regulates the cell cycle like other tumor suppressors by arresting G1/S transition or mitotic progression. RASSF1A controls mitotic arrest by regulating the anaphase-promoting complex (APC)-Cdc 20 complex (4, 5) . Ectopic RASSF1A expression inhibits cell-cycle progression in the G1 phase by cyclin D1 down-regulation in H1299 and A549 cells (6, 7) . RASSF1A also controls another cyclin, cyclin A2. Increased RASSF1A expression induces cyclin A2 expression transcriptionally through an increase of the binding activity of p120 E4F to the cyclin A2 promoter (8) . Ras is a key protein that regulates various cellular signaling pathways, including cell proliferation and malignant transformation (9) . Activated Ras resulting from point mutation plays an important role in cancer development, and also is involved in the induction of many downstream mediators. One of these is the c-Jun NH2-terminal kinase (JNK). Ras regulates the JNK signal transduction pathway (10, 11) . Oncogenic Ras-mediated JNK activation contributes to cellular transformation (12) . The constitutive activation of JNK has also been observed in cancer cell lines and tumor tissues, and contributes to tumor cell growth (13) (14) (15) (16) (17) (18) . JNK activation by a constitutively active SAPKß-MKK7 causes NIH3T3 cells to express a partially transformed phenotype (19) . One of the downstream targets of JNK is known to be a transcription factor, c-Jun, and c-Jun phosphorylation is involved in Rasinduced transformation (20) .
In a previous study, we reported that RASSF1A reduced JNK activation and c-Jun phosphorylation, and suggested that RASSF1A exerts a tumor-suppressing effect by blocking oncogene-mediated JNK activation (21) . As mentioned above, oncogenic Ras-mediated JNK activation contributes to cellular transformation (12) . Therefore, we assumed that RASSF1A might exert a tumor-suppressing role in Ras-induced cellular transformation, especially JNK-mediated transformation. In the present study, we investigated the involvement of RASSF1A in the control of JNK activation that is related to oncogenic H-Ras.
Materials and methods
Cell lines and reagents. Cell lines used in these experiments were purchased from the American Type Culture Collection (ATCC, Manassas, VA). A549 and BEAS-2B cells were cultured at 37˚C in a humidified chamber of 5% CO 2 . The culture medium was Ham's F-12 (Gibco/BRL, Grand Island, NY) containing 10% heat-inactivated fetal bovine serum (FBS) (Gibco/BRL), sodium bicarbonate (2 mg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml). MCF-7 and 293T cells were cultured in IMDM and DMEM supplemented with 10% FBS, respectively. The NCI-H1299 (H1299) cells were cultured in RPMI-1640 (Gibco/BRL, Grand Island, NY) containing 10% heat-inactivated fetal bovine serum (Gibco/BRL), sodium bicarbonate (2 mg/ml), penicillin (100 U/ml), streptomycin (100 μg/ml) at 37˚C in a humidified chamber of 5% CO 2 . The kinase inhibitors, SP600125 and PD98059, were purchased from Calbiochem (San Diego, CA) and LY294002 was purchased from Sigma-Aldrich (St. Louis, MO).
Transfection. Cells (1x10 5 ) were seeded on 60-mm culture dishes and grown for 24 h before transfection. Cells were transfected with either H-Ras G12V (0.5 μg) alone, or with RASSF1A (1 μg), using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA).
Western blotting and cycloheximide treatment. Cells were transfected with plasmids, and lysed with RIPA buffer [50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% NaDeoxycholate (pH 7.4)] supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 μg/ml peptasin A, 10 μg/ml aprotinin and 5 μg/ml leupeptin). Protein concentrations were measured using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Protein lysates were separated by SDS-PAGE, and then transferred onto nitrocellulose membranes (Hybond™-P, Amersham Biosciences, Piscataway, NJ) They were then blocked with phosphate-buffered saline (PBS) containing 0.2% Tween-20 and 5% non-fat dry milk, incubated with primary antibody, and then with horseradish peroxidase-labeled secondary antibody. The signal was exposed on X-ray film. The antibodies used were polyclonal anti-phospho-SAPK/JNK (Thr183/Tyr185) antibody (Cell Signaling Technology, Beverly, MA), polyclonal anti-JNK antibody (Cell Signaling Technology), monoclonal anti-RASSF1A antibody (eBiosciences, Minneapolis, MN), monoclonal anti-c-Ras antibody (Ab-1, Calbiochem), monoclonal anti-p27
Kip1 antibody (BD Transduction Laboratories, San Diego, CA), polyclonal anti-p21 WAF1/CIP1 (C-19, Santa Cruz Biotechnology, Santa Cruz, CA), and monoclonal anti-ß-actin antibody (AC-74, Sigma). For cycloheximide treatment in 293T and MCF-7 cells, the medium was supplemented with 50 μg/ml of cycloheximide (CHX, Sigma) 24 h after transfection with either H-Ras alone or with RASSF1A. The cells were then collected at the indicated time-points.
siRNA transfection. The double-stranded siRNA oligonucleotide used for targeting RASSF1A or fluorescence-labeled double-stranded RNA (dsRNA) oligomer (BLOCK iT™ fluorescence oligo) as a control were synthesized at Invitrogen. The RASSF1A siRNA sequences used were those published previously (5): sense, 5'-TGTGGAGTGGGAGACACCTTT-3'; and antisense, 5'-AGGTGTCTCCCACTCCACATT-3'. Cells were transfected with 100 nM RASSF1A siRNA or control dsRNA using lipofectamine 2000 reagent (Invitrogen), according to the manufacturer's instructions. In some of the experiments, the cells were treated with 100 nM JNK siRNA as a specific inhibitor of JNK synthesis. The double-stranded siRNA oligonucleotides used for targeting JNK (sense, 5'-AAA AAGAATGTCCTACCTTCTTT-3'; antisense, 5'-AGAAGG TAGGACATTCTTTTTTT-3') were synthesized at Invitrogen.
Reverse transcription-PCR. Total RNA was isolated using TRIzol reagent, according to the manufacturer's instructions (Life Technologies, Rockville, MD). Reverse transcription (RT) reactions were performed using 2 μg of total cellular RNA with Molony murine leukemia virus reverse transcriptase (Life Technology) and oligo (dT) primers (Roche, Indianapolis, IN). The RT reaction mixtures were used as a template for the PCR amplification of RASSF1A and ß-actin. Primers and conditions used for RASSF1A and ß-actin RT-PCR were as previously described (21) .
In vitro kinase assay. Non-radioactive JNK kinase assays were performed according to the manufacturer's protocol (Cell Signaling). Briefly, 20 μl of re-suspended immobilized beads were incubated with 200 μg of total protein lysate by gentle rocking overnight at 4˚C. Then, the cell lysate/ immobilized c-Jun fusion protein was microcentrifuged at 12,000 rpm for 30 sec at 4˚C and pellets were washed twice with 1X lysis buffer and twice with 1X kinase buffer. Pellets were suspended in 50 μl of 1X kinase buffer supplemented with 100 μM ATP and incubated for 30 min at 30˚C. The reactions were stopped with 25 μl of 3X SDS sample buffer and the samples were then boiled for 5 min. The 20 μl samples were loaded onto a 12% SDS-polyacrylamide gel for electrophoresis and transferred to a nitrocellulose membrane. The blots were incubated with phospho-c-Jun (Ser63) antibody.
Results
To determine that RASSF1A suppresses the H-Ras G12V -induced JNK activation, oncogenic H-Ras and/or RASSF1A were introduced into H1299 cells, cells in which the RASSF1A promoter is epigenetically inactivated and therefore RASSF1A is not expressed. Fig. 1A shows that increased H-Ras G12V expression induced JNK phosphorylation. This result is consistent with a previous report (12) . Next, we co-transfected the cells with H-Ras G12V and RASSF1A. Exogenous expression of RASSF1A suppressed H-Ras-induced JNK phosphorylation (Fig. 1A) . This result was confirmed in another cell line, A549, in which RASSF1A is also epigenetically inactivated. Fig. 1B shows that RASSF1A expression inhibited H-Ras G12V -induced JNK activation in A549 cells. We examined this effect in three additional cell lines, 293T, MCF-7 and BEAS-2B. In keeping with the results seen in Fig. 1A and B, RASSF1A introduction blocked H-Ras G12V -induced JNK activation, even though RASSF1A is expressed in 293T and BEAS-2B cells ( Fig. 1C and E) . To further examine the inhibition of JNK phosphorylation by RASSF1A, we performed an in vitro kinase assay using the immobilized c-Jun bead as the substrate for JNK. Consistent with the results shown in Fig. 1C , HRas G12V expression enhanced c-Jun phosphorylation (Fig. 1F) . As a positive control, SP600125, a specific JNK inhibitor (21), was used to treat 293T cells. SP600125 treatment blocked c-Jun phosphorylation (Fig. 1G) . However, the MEK inhibitor PD98059 did not inhibit JNK activity, and neither did the mTOR inhibitor rapamycin, which inhibits the phosphorylation and activation of p70S6K. In agreement with the Western blotting, as shown in Fig. 1C , an in vitro kinase assay showed that the introduction of RASSF1A markedly reduced JNK activity in the cells that had shown an increase in JNK activity due to H-Ras G12V expression, as was observed for the cells treated with SP600125 (Fig. 1G) . These results suggest that RASSF1A suppressed the oncogenic H-Ras-induced JNK activation.
In our previous report, we showed that transient transfection of RASSF1A siRNA into BEAS-2B or RASSF1A-overexpresing H1299 cells enhanced JNK activity (21) . We also used siRNA to inhibit RASSF1A expression, as previously reported (5) . Transient transfection of RASSF1A siRNA into 293T or BEAS-2B cells efficiently down-regulated RASSF1A expression (Fig. 2A) . We then examined whether siRNA-mediated blocking of RASSF1A expression could enhance the JNK activity that was up-regulated by H-Ras G12V expression. Fig. 2B and C show that the siRNA-mediated blocking of endogenous RASSF1A expression slightly enhanced JNK phosphorylation. JNK activity was also examined by an in vitro kinase assay in these cell lines. As shown in Fig. 2D and E, the siRNA-mediated blocking of RASSF1A expression slightly enhanced the JNK activity in both cell lines. This result is consistent with Fig. 2B and C. Taken together, these results clearly indicate that RASSF1A suppressed H-Ras induced JNK activation.
The Ras/Raf pathway has an important role in mediating growth factor signaling. Through this pathway, many target proteins are induced or repressed. Ras up-regulates the expression of c-Jun and p21 WAF1/CIP1 . Meanwhile, downregulation of p27
Kip1 is required for entry to the S-phase (22, 23) . Therefore, we examined whether RASSF1A regulated the expression of H-Ras downstream target proteins. 293T cells were transiently transfected with H-Ras G12V and/or RASSF1A, and Western blotting was performed. Consistent with Fig. 1 , H-Ras induced JNK activity and this was blocked by exogenous expression of RASSF1A (Fig. 3) . Fig. 3A shows that H-Ras G12V expression down-regulated p27
Kip1 expression, and that RASSF1A co-transfected with H-Ras G12V recovered p27 Kip1 down-regulation by RASSF1A was also observed in MCF-7 cells (Fig. 3B) . However, p21 induction by H-Ras G12V was not influenced by RASSF1A expression in these cells. This difference is probably due to a cell-type specific phenomenon. We used siRNA to inhibit endogenous RASSF1A expression, as has been previously reported (5) . Transient transfection of RASSF1A siRNA into 293T cells slightly enhanced JNK phosphorylation (Fig. 3C) . Enhancement of p21 WAF1/CIP1 induction and p27 Kip1 downregulation were also observed in cells that were transfected with RASSF1A siRNA. In the present study, H-Ras G12V upregulated p21 WAF1/CIP1 expression. This effector, p21 WAF1/CIP1 , is a cell-cycle inhibitor that blocks the cell cycle transition from the G1 phase to S-phase. However, it is often induced by growth factor signaling, probably promoting the association of cyclin D and Cdk (24) . Recent reports have demonstrated that JNK is required for PDGF-induced p21 WAF1/CIP1 promoter activity independent of p53, and that RASSF1A suppresses JNK activity (21, 25) . Therefore, we examined whether JNK mediated the H-Ras G12V -induced p21 WAF1/CIP1 induction and p27
Kip1 down-regulation. We used siRNA to inhibit endogenous JNK expression. Transient transfection of JNK siRNA into 293T cells efficiently down-regulated JNK expression (Fig. 3D) . Blocking of H-Ras G12V -induced JNK activation by siRNA led to recovery of p27 Kip1 expression. However, there was no alteration observed in the amount of p21 WAF1/CIP1 in these cells. The amount of p27
Kip1 protein in cells is regulated by transcriptional and post-transcriptional mechanisms (26, 27) . Since the ectopic expression of RASSF1A inhibited H-Ras G12V - induced p27
Kip1 down-regulation, we attempted to determine whether the recovery of p27 Kip1 expression by RASSF1A was post-transcriptional. We transfected 293T and MCF-7 cells with H-Ras G12V and RASSF1A, treated with cycloheximide, and then examined p27
Kip1 expression via Western blotting. As shown in Fig. 4A and B, RASSF1A led to recovery of the levels of p27
Kip1 by increasing its half-life.
Discussion
Even though RASSF1A heterodimerizes with Nore 1 and is known to be a Ras effector, the precise mechanism by which RASSF1A suppresses activated Ras is not fully understood (3, 28) . Ras plays an important role in the regulation of various cellular functions, including cell proliferation, differentiation, and malignant transformation (9) . Constitutive activation of JNK is important for Ras-induced transformation, and p27 Kip1 down-regulation is a downstream event in Rastriggered cell cycle progression (22, 23) . There are several reports demonstrating that one of many downstream mediators that is regulated by oncogenic Ras is JNK, and that it contributes to Ras-induced transformation (10) (11) (12) . The constitutive activation of JNK by SAPKß-MKK7 induces transformation of NIH3T3 cells (19) . A recent study has reported that RASSF1A expression inhibits JNK activity (21) . In the present study, we showed that oncogenic H-Ras induced JNK activation and p27
Kip1 down-regulation, and that RASSF1A inhibited these events brought about by H-Ras G12V . As demonstrated above, the enhanced JNK activity related to H-Ras G12V overexpression that resulted from exogenous transfection was not much affected by RASSF1A at a low level inside cells. Endogenous RASSF1A expression in 293T and BEAS-2B cells was not detectable by Western blotting in the present study ( Fig. 1C and E) . However, RASSF1A expression in these cells was detected by RT-PCR in a previous report (21) and again in this present study ( Fig. 2A) . We assumed that H-Ras G12V overexpression could overcome the endogenous RASSF1A-mediated JNK suppression because RASSF1A was expressed at a low level in 293T and BEAS-2B cells. However, exogenous RASSF1A expression, which was detected by Western blotting (Fig. 1 ) and was enough to inhibit H-Ras G12V activity, suppressed H-Ras-triggered JNK activation. Since oncogenic Ras activates many signaling pathways involved in cellular transformation, it would be interesting to see whether RASSF1A also suppresses other Ras downstream events. Based on the results of this present study, we suggest that RASSF1A functions as a tumor suppressor by suppressing the oncogenic H-Ras-induced JNK pathway (Fig. 4C) . Kip1 by increasing its halflife. 293T (A) and MCF-7 (B) cells were transfected with H-Ras G12V alone, or with RASSF1A, and then treated with cycloheximide 24 h later. Extracts were subjected to SDS-PAGE and p27
Kip1 stability was assessed by Western blotting with anti-p27 Kip1 antibody. (C) Summary of the RASSF1A-inhibited oncogenic Ras signaling pathway.
